Evidence map›Paper›PMID 32085487›Full record

ReviewInternational journal of molecular sciences2020

Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020.

Jacqueline K Innes, Philip C Calder

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06129526 (Study of the Effect of Eicosapentaenoic Acid), which is not on this map. Cited by 157 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
157citing papers in PubMed, 4 pooled it
28.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06129526 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes

TypeinterventionalSponsorUniversity of IoanninaRan2023 to 2024Enrolled450ConditionsDiabetes Type 2, Hypertriglyceridemia, Diabetes MellitusArmsEPAVasc, Corn Oil
3 · Its place in the literature

Who cites it

157 citing papers in PubMed, 4 syntheses or guidelines pooled it, 352 citations in OpenAlex.

  1. Pooled it
  2. Omega-3 fatty acids for intermittent claudication.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

97 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jacqueline K InnesSchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
Philip C CalderSchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.ORCID 0000-0002-6038-710X
University Hospital Southampton NHS Foundation Trust · GBUniversity of Southampton · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The omega-3 (n-3) fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in seafood (especially fatty fish), supplements and concentrated pharmaceutical preparations. Long-term prospective cohort studies consistently demonstrate an association between higher intakes of fish, fatty fish and marine n-3 fatty acids (EPA + DHA) or higher levels of EPA and DHA in the body and lower risk of developing cardiovascular disease (CVD), especially coronary heart disease (CHD) and myocardial infarction (MI), and cardiovascular mortality in the general population. This cardioprotective effect of EPA and DHA is most likely due to the beneficial modulation of a number of known risk factors for CVD, such as blood lipids, blood pressure, heart rate and heart rate variability, platelet aggregation, endothelial function, and inflammation. Evidence for primary prevention of CVD through randomised controlled trials (RCTs) is relatively weak. In high-risk patients, especially in the secondary prevention setting (e.g., post-MI), a number of large RCTs support the use of EPA + DHA (or EPA alone) as confirmed through a recent meta-analysis. This review presents some of the key studies that have investigated EPA and DHA in the primary and secondary prevention of CVD, describes potential mechanisms for their cardioprotective effect, and evaluates the more recently published RCTs in the context of existing scientific literature.

Indexed as

AnimalsAquatic OrganismsCardiotonic AgentsCardiovascular SystemFatty Acids, Omega-3HumansRandomized Controlled Trials as TopicRisk FactorsCardiotonic AgentsFatty Acids, Omega-3cardiovascular diseasecoronary heart diseasedocosahexaenoic acideicosapentaenoic acidomega-3 polyunsaturated fatty acids

Identifiers

PMID32085487
PMCPMC7072971
OpenAlexW3006875859

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.